`
`RESEARCH
`
`
`
`
`
`APPLICATION NUMBER:
`
`
`213051Orig1s000
`
`
`OFFICER/EMPLOYEE LIST
`
`
`
`
`
`
`
`
`
` DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
` PUBLIC HEALTH SERVICE
` FOOD AND DRUG ADMINISTRATION
`
` CENTER FOR DRUG EVALUATION AND RESEARCH
`
`
`
`
`September 17, 2019
`
`Administrative file for NDA 213051
`
`
`
`Peter Franks, Regulatory Health Project Manager
`
`Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II
`
` MEMORANDUM
`
`
`
`
`
`DATE:
`
`
`TO:
`
`
`FROM:
`
`
`
`SUBJECT: Officer/Employee List for NDA 213051
`
`
`
`
`APPLICATION/DRUG:
`
`
`
`
`The following officers or employees of FDA participated in the decision to approve this
`
`application and consented to be identified on this list:
`
`
`
`NDA 213051/Rybelsus (semaglutide) tablets
`
` Qiang, Yandong
`
`
` Ramaswamy, Muthukumar
`
`
`
` Rauschecker, Mitra
`
`
` Sista, Sury
`
`
`
` Tran, Suong T
`
`
` Wackes, Frank
`
` Wang, Yun (FDA)
`
`
` Williams, Marcia Britt
`
`
`
`
`
` Absar, Mohammad
` Abugov, Robert
`
`
` Ayalew, Kassa
` Basso, Federica
`
`
` Braithwaite, Elena
`
` Bryant, Samantha
`
` Cao, Christian
`
` Chung, Amy
` Conrad, Ariane
`
`
` Dinatale, Miriam
`
`
`
` Earp, Justin C
`
`
` Griffiths, LaShawn
`
`
` Khurana, Manoj
`
`
` Li, Vincent
`
`
` Liedtka, Jane
`
`
` Lin, Karl K
`
`
` Lu, Min
`
` Lungu, Andreea
`
`
` Manangeeswaran, Mohanraj
`
`
` Mandula, Haritha
`
`
` Mehta, Hina
`
` Nguyen, Maria
`
`
` Niak, Ali
`
` Penzenstadler, Justin
`
`
`
`
`
`
`
`
`
`Reference ID: 4497378
`
`(
`
`
`
`